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Pseudomonas aeruginosa is a leading cause of pneumonia, and many components of the innate immune
system have been proposed to exert important effects in preventing lung infection. However, a vigorous
experimental system to identify an overriding, key effector mediating innate immunity to lung infection has not
been utilized. As many of the important components of innate immunity are involved in recruitment and
activation of polymorphonuclear neutrophils (PMNs) to infected tissues, we hypothesized that the cells and
factors needed for their proper recruitment to the lung comprised the major mediators of innate immunity. In
neutropenic mice, intranasal (i.n.) doses of P. aeruginosa as low as 10 to 100 CFU/mouse produced a fatal lung
infection, compared with 107 to >108 CFU for nonneutropenic mice. There was only a very modest increased
mortality in mice lacking mature lymphocytes and no increased mortality in mice depleted of alveolar
macrophages when administered i.n. P. aeruginosa. Recombinant mouse granulocyte colony-stimulating factor
increased survival of neutropenic mice after i.n. P. aeruginosa inoculation. MyD88/ mice, which cannot
recruit PMNs to the lungs, were highly susceptible to fatal P. aeruginosa lung infection, with bacterial doses of
<120 CFU being lethal. Activation of a MyD88-independent pathway for PMN recruitment to the lungs in
MyD88/ mice resulted in enhanced protection against P. aeruginosa lung infection. Overall, in the absence
of PMNs, mice cannot resist P. aeruginosa lung infection from extremely small bacterial doses. There is an
inescapable requirement for local PMN recruitment and activation to mediate innate immunity to P. aeruginosa
lung infection.
Pseudomonas aeruginosa is a cause of significant morbidity
and mortality in hospitalized patients, particularly those with
compromised immune systems. P. aeruginosa is a leading cause
of ventilator-associated pneumonia and of chronic pulmonary
infections in cystic fibrosis patients (7, 20). Given that the lung
represents the largest sterile epithelial surface of the body in
contact with the external environment, it is not surprising that
an elaborate defense system is in place to protect this organ
from infectious pathogens. The pulmonary innate host defense
consists of structural (integumentary) barriers provided by re-
spiratory tract epithelial cells, mucociliary clearance, antimi-
crobial molecules (i.e., defensins, lysozyme, lactoferrin, and
collectins) produced in the airways, and phagocytic defenses
such as resident alveolar macrophages (AM) and recruited
polymorphonuclear neutrophils (PMNs).
With regard to both resident and recruited immune cells
(specifically, AM, PMNs, and lymphocytes), it is unclear what
the relative contribution of each of these cellular immune
components is in preventing acute P. aeruginosa pulmonary
infection. Alveolar macrophages are thought to provide the
first line of defense against microorganisms that reach the
lower airways, and they have well-defined roles in both the
innate and adaptive immune responses (48). However, in stud-
ies using methods to selectively deplete AM to investigate the
importance of macrophage phagocytosis in lung host defense
against acute P. aeruginosa lung infection, the results have been
somewhat contradictory (9), and no major increase in infec-
tious pathology or increased mortality following low challenge
doses of P. aeruginosa has been found. Most of the evidence
indicates a role for AM in regard to cytokine secretion and
nonessential PMN recruitment but no direct role in mediating
bacterial killing to protect the lung. The role of lymphocytes in
innate defense against acute P. aeruginosa lung infection has
not been well characterized, although there is some suggestion
that a T-cell immunomodulatory effect may be important (15).
Evidence for enhanced susceptibility of patients with AIDS to
nosocomial P. aeruginosa infection has also been reported (18),
although this has been mostly judged to be secondary to de-
fects in PMN numbers or function. More recently, a murine
study suggested that CD1d-restricted T cells play a role in host
defense in acute P. aeruginosa pulmonary infections (33). In
contrast, it is generally well-accepted that neutrophils comprise
a major component of host resistance to P. aeruginosa infec-
tion, particularly in the acute settings of bacteremia and sepsis
(32). Neutrophil depletion (49, 55) or inhibition of PMN re-
cruitment to the lungs by blocking CXC chemokine receptor 2
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(58) resulted in increased mortality after P. aeruginosa infec-
tion, but these studies used high doses of single strains of P.
aeruginosa that were chosen due to their known high virulence
in the setting of murine pneumonia and did not encompass a
systematic study of the relationship of PMN depletion to re-
sultant infectious doses of multiple isolates of P. aeruginosa
that could cause pneumonia, sepsis, and death. Nor did these
studies rule out additional effects from their interventions on
disruption of local mediators of immunity, such as AM func-
tion or mucociliary clearance, contributing to some of the
enhanced susceptibility to P. aeruginosa pneumonia.
Having observed that neutropenia alone was sufficient to
allow P. aeruginosa systemic dissemination from the gastro-
intestinal tract of colonized mice (24), we set out to deter-
mine how essential neutrophils were for the host innate
defense system against acute P. aeruginosa pulmonary infec-
tion, or if, in their absence, other cellular factors such as
resident AM, mucociliary clearance, or lymphocyte recruit-
ment and activation could remove very low bacterial inocula
efficiently. To evaluate these factors, we utilized selective
neutrophil depletion, selective AM depletion, and mice
lacking mature lymphocytes (recombinase activating gene-
deficient mice [rag/]) or unable to recruit PMNs to in-
fected tissues (myeloid differentiation factor 88-deficient
mice [MyD88/]) in a model of murine acute pneumonia
initiated by intranasal (i.n.) inoculation of bacteria onto the
nares of anesthetized mice. In neutropenic mice, or
MyD88/ mice, doses of P. aeruginosa in the range of 10 to
100 CFU/animal produced a lethal pneumonia in 88% of
infected animals. Restoration of PMN recruitment by injec-
tion of recombinant murine granulocyte colony-stimulating
factor (r-mGCSF) or by inducing MyD88-independent re-
cruitment of PMNs to the lungs of Myd88-deficient mice
significantly increased resistance to P. aeruginosa pneumo-
nia. These findings collectively indicate that in the absence
of neutrophil recruitment to the lung, other factors of the
innate immune system of mice cannot adequately control
infections initiated by very low infectious doses of most
strains of P. aeruginosa.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The strains of P. aeruginosa used are
listed in Table 1. The variety of strains, a mixture of laboratory strains and
clinical isolates, was chosen to illustrate that the results obtained were not strain
specific but were applicable to diverse strains of P. aeruginosa. For infecting mice,
P. aeruginosa cultures were made from frozen stocks, streaked onto cetrimide
agar plates, grown overnight at 37°C, and resuspended in sterile phosphate-
buffered saline (PBS) with 1% fetal calf serum. P. aeruginosa concentrations were
estimated using a spectrophotometer, and actual CFU counts (averages of four
replicates) were verified by enumeration on LB and cetrimide agars. Escherichia
coli strain HB101 was grown in LB medium. For experiments using killed E. coli
cells, 4% paraformaldehyde was added to the culture and incubated overnight at
4°C; bacterial cells were then harvested and washed five times with PBS, and then
the cells were resuspended in PBS. The concentration was determined by count-
ing dilutions of the cell suspension in a hemocytometer. Cell death was con-
firmed by inoculating 0.1 ml of the paraformaldehyde-treated cells onto tryptic
soy agar, on which no growth was observed after 48 h at 37°C.
Animals. Six- to eight-week-old female C3H/HeN mice were obtained from
Harlan Sprague Dawley, Inc. Six- to eight-week-old female RAG1-deficient mice
(C57BL/6 background) were obtained from The Jackson Laboratory. MyD88/
mice were kindly provided by Douglas Golenbock, University of Massachusetts
Medical School, and were backcrossed to C57BL/6 mice for10 generations and
then intercrossed to generate MyD88/ mice in the B6 background. Six- to
eight-week-old male and female MyD88/ mice (sex matched for experiments)
were subsequently bred at the animal facility at Harvard Medical School. Age-
and sex-matched C57BL/6 mice (The Jackson Laboratory) were used as controls.
Mice were housed in groups of four in sterilized cages equipped with filter hoods
and supplied with sterile bedding, sterile water, and sterile mouse chow and were
maintained under specific-pathogen-free conditions in compliance with the Har-
vard Medical Area Institutional Animal Care and Use Committee guidelines.
Murine model of acute pneumonia. Mice were treated with different immu-
nosuppressive regimens (Table 2) 24 h prior to infection. To initiate lung infec-
tion, mice were injected intraperitoneally (i.p.) with ketamine (90 mg/kg of body
weight/dose) and xylazine (10 mg/kg/dose), and after anesthesia was induced, the
P. aeruginosa inoculum was administered i.n. (10 l per nare). Neutropenic mice
received 0.100 mg of gentamicin/ml (Research Product International, Mt. Pros-
pect, IL) added to the drinking water to prevent translocation of normal enteric
bacteria from the gastrointestinal tract to the oropharynx. Mice were monitored
twice daily for 7 days, by which time PMN counts had returned to normal (16).
Moribund mice (i.e., with labored or rapid breathing, decreased motility, ruffled
or abnormal-looking fur, or other obvious signs of distress) were euthanized and
counted as dead for purposes of these experiments, and along with animals that
died between the observation periods, bodies were frozen at 20°C. Spleens and
lungs were resected, homogenized in 1% proteose peptone, serially diluted in
proteose peptone, and plated on MacConkey and cetrimide agars to confirm that
lethality was associated with dissemination of P. aeruginosa, and not other or-
ganisms, to these organs. All deaths reported were from moribund/euthanized
mice, and dead mice were confirmed to have P. aeruginosa disseminated to the
spleens and lungs.
To evaluate the effect of MyD88-independent neutrophil recruitment into the
lungs of MyD88/ mice, the acute pneumonia model was modified in the
following manner: MyD88/ and wild-type (WT) C57BL/6 mice were random-
ized to receive either live E. coli strain HB101 (1  108 CFU, i.n.) or paraform-
aldehyde-killed E. coli strain HB101 (1  108 CFU, i.n.) 24 h prior to challenge
with P. aeruginosa strains. To confirm PMNs were the key components elicited by
this treatment, additional Myd88/ mice treated with E. coli were also made
neutropenic as described below.
Differential staining of BAL. Mice were euthanized by carbon dioxide inhala-
tion. Bronchoalveolar lavage (BAL) fluid was obtained by exposing the trachea
and injecting, then removing, 0.8 ml of PBS with 0.5 M EDTA three times from
the lungs. BAL samples were centrifuged to pellet cells; cells were washed and
resuspended in PBS. Cells were centrifuged onto microscope slides (cytospins),
slides were air dried, and cells were stained using a modified Wright-Giemsa
TABLE 1. Bacterial strains used in this study
Strain Description Source, reference,or description
PAO1 Wild-type serogroup O2/O5 st noncytotoxic,
chloramphenicol sensitive, pilC
M. Vasil
IT-4 Clinical isolate from bacteremia, serogroup O1 Clinical laboratory
170003 Wild-type serogroup O2/O5 strain, LPS
smooth, noncytotoxic
23
PA14 Wild-type serogroup O10 strain, cytotoxic
(ExoU)
F. Ausubel
N13 Wild-type serogroup O6 strain, early isolate
from CF lung
11
6077 Wild-type serogroup O11 strain, cytotoxic
(ExoU)
17
N8 Wild-type serogroup O11 strain, cytotoxic
(ExoU), early isolate from cystic fibrosis
patient lung
11
TABLE 2. Immunosuppressive regimens
Agent Dose Route ofadministration Frequency Reference
Cyclophosphamide 150 mg/kg i.p. Once daily every
other day for
3 days
13
MAb RB6-8C5 200 g i.p. Once 14
Liposomal
CL2MBP
100 l i.n. Once 28
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stain (Diff-Quick; Baxter Scientific, Miami, FL). For each sample, a total of 100
cells were counted from randomly chosen high-power fields.
Cyclophosphamide-induced neutropenia, lymphopenia, and monocytopenia.
A cyclophosphamide (Cy; Sigma-Aldrich, St. Louis, MO) dose of 150 mg/kg was
administered i.p. every other day for three doses to produce neutropenia (abso-
lute neutrophil count, 500/mm3) lasting for 5 days (24).
Production of RB6-8C5 monoclonal antibody and induction of selective neu-
tropenia. The RB6-8C5 rat anti-mouse monoclonal antibody (MAb) specific for
the Ly-6 antigen highly expressed by PMNs was produced by growing hybridoma
cells in culture (Dulbecco’s modified Eagle’s medium with 10% fetal calf serum),
followed by purification of the antibody by affinity chromatography, as previously
described (24). A single dose of 0.2 mg of RB6-8C5 was administered i.p. to mice
to produce a severe neutropenia (absolute neutrophil count, 100/mm3) lasting
for 5 days (24).
Histological analysis of lungs. C3H/HeN mice were given either 100 CFU of
P. aeruginosa strain PAO1 i.n. after anesthesia with ketamine and xylazine, 0.2 mg
of RB6-8C5 i.p., or 0.2 mg of RB6-8C5 i.p., followed 24 h later by 100 CFU of
PAO1 i.n. Animals were sacrificed 24 h after administration of MAb RB6-8C5 or
challenge with P. aeruginosa, the trachea was exposed with a midline neck
incision, and 1 ml of PBS containing 1% paraformaldehyde was instilled into the
lungs by means of a tracheal catheter. The lungs were removed, fixed in PBS with
1% paraformaldehyde for 1 h at room temperature, and then placed in 70%
ethanol in water at 4°C overnight prior to paraffin embedding. Sections were
stained with hematoxylin and eosin and reviewed by a veterinary pathologist.
Alveolar macrophage depletion. CL2MBP (clodronate) was a gift from Roche
Diagnostics (Mannheim, Germany). Liposomes containing CL2MBP (250 mg/
ml) were prepared as described previously (59). For assessment of AM depletion,
three uninfected mice per group were anesthetized as described above and then
inoculated i.n. with 100 l of CL2MBP liposomes or PBS-containing liposomes
(28). Twenty-four hours later, BAL samples from the three mice were obtained
and analyzed as above.
Neutrophil reconstitution. Recombinant murine granulocyte colony-stimulat-
ing factor was a gift from Amgen (Thousand Oaks, CA). To determine whether
r-mGCSF reconstituted neutrophils after RB6-8C5 neutrophil depletion, two
groups of four C3H/HeN mice each received MAb RB6-8C5 i.p. on day zero.
The groups were then randomized to receive either r-mGCSF (0.150 mg/kg/dose,
i.p.) (51) or mouse albumin (0.150 mg/kg/dose, i.p.) daily on days 1 to 5. Each
group of mice was bled on days 1 to 6, and blood samples were sent for complete
blood count and differential analysis to the hematology laboratory at Children’s
Hospital Boston, Boston, MA.
To evaluate the effect of neutrophil reconstitution, the acute pneumonia
model was modified in the following manner: (i) MAb RB6-8C5 was adminis-
tered on day zero; (ii) mice were randomized to receive either r-mGCSF at
0.150/mg/kg/dose, i.p., or mouse albumin at 0.150 mg/kg/dose, i.p., daily for 5
days (days 1 to 5), starting 24 h after RB6-8C5 administration; and (iii) mice were
challenged with P. aeruginosa strains on day 3 after administration of MAb
RB6-8C5.
Neutrophil recruitment. To evaluate MyD88-independent PMN recruitment,
anesthetized MyD88/ mice (n  3 per group) were given i.n. one of the
following inocula: P. aeruginosa strain PAO1 (50 CFU), 10 g lipopolysaccharide
(LPS) from E. coli strain 0111:B4 (List Biological Labs, Campbell, CA), 1  108
CFU of paraformaldehyde-killed E. coli strain HB101, 10 g of poly I:C (Sigma
Aldrich, St. Louis, MO), or 1  108 CFU of live E. coli strain HB101. Twenty-
four hours later the mice were euthanized and BAL was performed. BAL
samples were then analyzed for neutrophil levels by using cytospin slides and
Wright-Giemsa stain.
Immunofluorescent staining of lung tissue. Lungs from mice infected for 24 h
were dissected after euthanasia by CO2 overdose and fixed in Bouin’s solution,
and paraffin-embedded sections were cut and mounted on slides. Five-microme-
ter sections of lung tissue were deparaffinized in xylene and rehydrated in a series
of reverse ethanol washes (100%, 95%, and 80% ethanol, sequentially). The
samples were then blocked by incubation in histology blocking buffer (PBS
containing 1% bovine serum albumin and 2% normal rat serum [Sigma-Aldrich,
St. Louis, MO]) for 15 min at 37°C. Samples were then incubated with MAb
RB6-8C5 (0.01 mg/ml) for 90 min at 37°C, then washed with PBS and incubated
with goat anti-rat immunoglobulin G conjugated to the Alexa 488 fluorophore
(0.005 mg/ml) for 90 min at 37°C. To detect background fluorescence, an ap-
propriate isotype control MAb (rat immunoglobulin G2b) was used. The sam-
ples were then washed and sections visualized with the 10 alpha-plan lens on
a Zeiss Axioplan 2 microscope fitted with filter sets for green fluorescent protein
and a cooled charge-coupled-device Hamamatsu Orca camera. Images were
acquired and processed using MetaMorph (Molecular Devices Corporation,
Sunnyvale, CA) and Adobe Photoshop software (30).
Statistical analyses. Survival data were analyzed with Fisher’s exact test, and
the survival curves were analyzed by the Kaplan-Meier log rank test using the
GraphPad Prism software (San Diego, CA).
RESULTS
Murine model of acute P. aeruginosa pneumonia. Mice that
were made neutropenic with Cy or MAb RB6-8C5 treatment
were inoculated with P. aeruginosa strains PAO1 (64 	 5.2
CFU, average 	 standard deviation [SD]), IT4 (7 	 2.0 CFU),
or 170003 (13 	 4.8 CFU). Mortality ranged from 62.5% to
100%, and median survival of mice treated with Cy or MAb
RB6-8C5 and subsequent i.n. P. aeruginosa challenge was sig-
nificantly lower than that of mice treated with either Cy or
RB6-8C5 alone (Fig. 1). All deceased mice given either Cy or
RB6-8C5 and then inoculated with P. aeruginosa strains were
confirmed to have P. aeruginosa in the lungs that also dissem-
inated to the spleen and liver.
Effect of lack of functional lymphocytes. RAG/ mice and
their C57BL/6 wild-type counterparts (n  8 in each group) all
survived after being inoculated i.n. with an average of 6.2 106
CFU (	1.5  106 CFU) of P. aeruginosa strain PAO1. When
the i.n. inoculum was increased slightly more than twofold, to
an average 1.4  107 CFU (SD, 2.1  106 CFU), all mice in
both groups died and had high levels of P. aeruginosa in both
lungs and spleens. Interestingly, when an intermediate inocu-
lum of 9.2  106 CFU (SD, 1.1  106 CFU) was administered
i.n., none of the RAG/ mice survived, whereas 62.5% of the
wild-type mice survived (Fig. 2) (P  0.0028 by log rank test).
Overall, there was an increased susceptibility of C57BL/6
RAG/ mice lacking functional lymphocytes to acute P.
aeruginosa pneumonia compared to their WT counterparts,
but this was only observed at a single challenge dose just 1.5
times the dose that was nonlethal for any RAG/ or WT mice
and 50% lower than a dose lethal to all of the challenged
RAG/ and WT mice.
Effect of macrophage depletion. Treatment with liposomal
clodronate reduced AM levels by an average of 83%, comparable
to previously reported results (28). Analysis of AM in the control
group gave a mean value of 55.3% macrophages in BAL fluid
(SD, 5.2%), whereas the liposomal clodronate group had an av-
erage of 9.7% macrophages (SD, 1.8%) in BAL fluid. When
C3H/HeN mice were given either liposomal clodronate (100 l)
or empty liposomes in PBS (100 l) 24 h prior to i.n. challenge
with three different doses of P. aeruginosa strain PAO1 (6.4 
105 	 2.8  104 CFU, 2.6  106 	 5.7  105 CFU, or 3.8 
107 	 2.8  106) we saw no difference in survival between
controls and AM-depleted mice (Table 3). P. aeruginosa was
present in the lungs and spleens of all deceased mice.
Histological analysis of murine lungs after RB6-8C5 treat-
ment. There was no histologic evidence of any lung injury in the
lungs of mice given PAO1 or MAb RB6-8C5 alone (Fig. 3) as
determined in a review of the dissected tissues by a veterinary
pathologist. In contrast, the lungs of mice given MAb RB6-8C5
followed by P. aeruginosa strain PAO1 given i.n. 24 h later and
then sacrificed 24 h subsequent to challenge showed significant
consolidation, atelectasis, and alveolar wall thickening (Fig. 3).
Neutrophil reconstitution with r-mGCSF. Mice given
r-mGCSF after neutrophil depletion with MAb RB6-8C5
showed an increase in the absolute neutrophil counts by days 5
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and 6 compared to the control group (Fig. 4). Injection of
r-mGCSF after neutrophil depletion with MAb RB6-8C5 and
subsequent i.n. challenge with P. aeruginosa strains PAO1, IT4,
170003, PA14, N13, or 6077 increased median survival com-
pared to the control group treated with albumin (Fig. 5), and
in five of the six groups there was also significantly increased
survival (P  0.06). P. aeruginosa was present in the lungs and
spleens of all deceased or moribund/euthanized mice. Mice
treated with MAb RB6-8C5 and subsequently given either
albumin or r-mGCSF but not infected with P. aeruginosa all
survived (n  8 mice per group).
Acute P. aeruginosa infection in MyD88/ mice. Age- and
sex-matched MyD88/ mice and wild-type C57BL/6 mice
were inoculated with P. aeruginosa strains PAO1 (55 	 3.2
CFU), PA14 (55	 7.0 CFU), or N8 (58	 1.2 CFU). Mortality
ranged from 62.5% to 100% for the MyD88/ mice and was
0% for all of the wild-type mice. The median survival of
MyD88/ mice given P. aeruginosa i.n. was significantly lower
than that of wild-type C57BL/6 mice: PAO1 group, P 0.0001;
PA14 group, P  0.0001; N8 group, P  0.025 (all by log rank
test). (Fig. 6). P. aeruginosa was present in the lungs and
spleens of all deceased or moribund/euthanized mice.
Effect of r-mGCSF treatment in MyD88/ mice and i.n.
challenge with P. aeruginosa. We investigated whether
r-mGCSF treatment could prevent fatal lung infections in
MyD88/ mice. MyD88/ mice (n  7) were given 150 g
FIG. 1. (A) Survival curves of female 6- to 8-week-old C3H/HeN mice treated with Cy (150 mg/kg i.p. once daily every other day for 3 days)
or MAb RB6-8C5 (200 g i.p.) and subsequently challenged i.n. with P. aeruginosa strain PAO1, IT4, or 17003. Median survival of mice given Cy
or MAb RB6-8C5 and P. aeruginosa was significantly lower than that of mice treated only with Cy or MAb RB6-8C5 (P 0.01, log rank test). Each
group contained eight mice. Values in parentheses indicate the average P. aeruginosa CFU inoculum. (B) Effect of cyclophosphamide (150 mg/kg
i.p. once daily every other day for 3 days) on murine white blood cell, absolute neutrophil, absolute lymphocyte, and absolute monocyte blood
counts. Data are means 	 standard errors of the means (in cells/mm3) for four mice per group.
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r-mGCSF/kg/dose i.p. daily on days 1 to 5. On day 3, P. aerugi-
nosa strain PA14 (55 	 3.2 CFU) was given i.n. to all mice.
Only one of seven of the r-mGCSF-treated MyD88/ mice
survived. P. aeruginosa was present in the lungs and spleens of
all deceased or euthanized mice. Thus, r-mGCSF could not
restore PMN recruitment to the lungs of MyD88/ mice.
Effects of MyD88-independent PMN recruitment on P.
aeruginosa lung infection. To determine if PMNs could be
recruited to the lungs of MyD88/ mice in a MyD88-inde-
pendent fashion, we administered various stimuli by the i.n.
route and compared the PMNs in BAL fluid 24 h after inoc-
ulation with that observed following low-dose P. aeruginosa
strain PAO1 infection. No neutrophils per 100 cells counted
were detected in the BAL fluid of MyD88/ mice given only
50 CFU of P. aeruginosa i.n., nor were any PMNs detected in
BAL fluid of mice given 10 g of LPS from E. coli strain
O111:B4, 1  108 CFU of paraformaldehyde-killed E. coli
strain HB101, or 10 g of poly(I:C) (Fig. 7). Only mice given
1  108 CFU of live E. coli HB101 i.n. had neutrophils in the
BAL fluid (62 	 3.1 neutrophils/100 cells counted [mean 	
standard error]) (Fig. 7E). Of note, there was a marked num-
ber of red blood cells in the BAL fluid of mice that were
administered live bacteria (Fig. 7A and E).
Lung tissues of MyD88/ mice inoculated i.n. with P.
aeruginosa strain PAO1 (100 CFU), live E. coli HB101 (1 108
CFU), or live E. coli HB101 (1  108 CFU) and then chal-
lenged 24 h later with either P. aeruginosa strain PAO1 (100
CFU) or no bacteria were next analyzed for the presence of
neutrophils in the lung tissues by using immunofluorescence.
Twenty-four hours after the challenge, mice were euthanized
and lungs were resected, preserved in Bouin’s solution, and
stained for the Ly-6 antigen using the RB6-8C5 MAb. Cells
presumed to be neutrophils (i.e., eosinophils and monocytes
also express Ly-6G and Ly-6C) were detected only in the lungs
of mice that were intranasally inoculated with live E. coli strain
HB101 (data not shown).
We next evaluated whether the MyD88/-independent re-
cruitment of neutrophils to the lungs following inoculation of
live E. coli HB101 could affect the survival of MyD88/ mice
from a subsequent P. aeruginosa pneumonia. Mice were ini-
tially randomized to receive either 1  108 CFU live E. coli
strain HB101 i.n. or 1  108 CFU paraformaldehyde-killed E.
coli strain HB101 i.n. Twenty-four hours later MyD88 / mice
were challenged with P. aeruginosa strains PAO1 (average 38
CFU) or PA14 (average 256 CFU). MyD88/ mice treated
with the live E. coli HB101 and challenged with strain PAO1
had a decreased time to death (P  0.001, log rank test) and
overall increased survival (five of eight versus zero of eight;
P  0.03, Fisher’s exact test), whereas mice challenged with
strain PA14 did not have a significant difference in time to
death (P  0.19, log rank test) but did have an overall signif-
icantly increased survival (five of eight versus zero of eight; P
0.03, Fisher’s exact test). When the infectious inoculum of P.
aeruginosa strain PAO1 was increased to 775 CFU, no
MyD88/ mice survived after pretreatment with either the
live E. coli HB101 or paraformaldehyde-treated E. coli HB101
groups (data not shown). Wild-type C57BL/6 mice randomized
to receive either live E. coli HB101 or paraformaldehyde-
treated E. coli HB101 and then given the same P. aeruginosa
strains and inocula as their MyD88/ counterparts had no
mortality (data not shown). In order to discern whether the
effect of live E. coli HB101 on augmenting P. aeruginosa clear-
FIG. 2. Survival curves of Rag/ mice and wild-type counterparts
(C57BL/6) after i.n. administration of P. aeruginosa strain PAO1. Me-
dian survival of wild-type mice was higher than that of Rag/ mice
(P  0.0028, log rank test). Each group contained eight mice. Values
in parentheses indicate the average P. aeruginosa CFU inoculum.
TABLE 3. Survival of C3H/HeN mice after i.n. administration of
liposomal clodronate followed by i.n. challenge with
P. aeruginosa strain PAO1
Agent
No. of survivors/no. challenged with the
indicated inoculum (CFU/mouse)
6.4  105 2.6  106 3.8  107
Liposomal clodronate 8/8 2/8 0/8
Liposomes in PBS 8/8 3/8 0/8
FIG. 3. Histological analysis of murine lungs after MAb RB6-8C5
administration. Histological sections of lungs from C3H/HeN mice
that were given PAO1 (100 CFU) only (A), MAb RB6-8C5 (0.200 mg
i.p. once only) (B), or MAb RB6-8C5 followed by P. aeruginosa strain
PAO1 (100 CFU i.n. 24 h after RB6-8C5 administration) (C). Mice
were sacrificed 24 h after either MAb RB6-8C5 or PAO1 challenge.
Magnification, 40. Images in panels A and B show normal histologic
appearance, whereas the section in panel C shows consolidation and
histologic changes consistent with an acute pneumonia.
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ance was truly due to PMN recruitment, versus a non-PMN-
dependent mechanism, a group of MyD88/ mice were de-
pleted of neutrophils first by administration of MAb RB6-8C5
and then given live HB101 followed by infection with P. aerugi-
nosa strain PAO1; this group showed 88.5% mortality (P 
0.0059 compared to the group given live HB101 and chal-
lenged with strain PAO1 group but not pretreated with RB6-
8C5; log rank test) (Fig. 8.) P. aeruginosa was present in the
lungs and spleens of all deceased or euthanized mice.
FIG. 5. Survival curves of neutropenic C3H/HeN mice treated
i.p. with either albumin (control) or r-mGCSF and challenged i.n.
with the P. aeruginosa strain indicated in each survival curve graph
and the dose (CFU/mouse) indicated in parentheses. P values by
log-tank test: PAO1, P  0.05; IT4, P  0.008; 170003, P  0.02;
PA14, P  0.06; N13, P  0.12; 6077, P  0.002. Each group
contained eight mice.
FIG. 4. Effects of r-mGCSF on murine white blood cell, absolute neutrophil, absolute lymphocyte, and absolute monocyte blood counts.
C3H/HeN mice were administered MAb RB6-8C5 (0.200 mg, i.p. once on day 1). Mice were then randomized to receive either 0.150 mg/kg
r-mGCSF i.p. or 0.150 mg/kg albumin i.p. daily for five doses, starting on day zero. Data are means 	 standard errors of the means of cells/mm3
for four mice per group. White bars, r-mGCSF; dark bars, albumin (control).
FIG. 6. Survival curves of WT C57BL/6 or MyD88/ mice after
i.n. challenge with P. aeruginosa strain PAO1, PA14, or N8. Median
survival of MyD88/ mice infected i.n. with P. aeruginosa was signif-
icantly lower (P  0.025, log-rank test) than that of WT C57BL/6 mice
infected i.n. with P. aeruginosa (all showed 100% survival). Each group
contained eight mice. Values in parentheses indicate the average P.
aeruginosa CFU inoculum.
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DISCUSSION
Although it is clear from human (3, 42) and animal (34, 49)
studies that PMNs are essential cellular components of resis-
tance to P. aeruginosa lung infection, it is also true that many
other innate immune or tissue clearance factors in the lung,
such as mucociliary clearance, antimicrobial peptides, ly-
sozyme, collectins such as surfactants and sugar-binding lec-
tins, epithelial cell responses, lymphocytes and lymphocyte
components, and alveolar macrophages, have also been impli-
cated as providing a means to significantly resist infection (61).
From these observations a reasonable hypothesis is that neu-
tropenia induced by a specific depletion of PMNs or a genetic
inability to recruit PMNs to the lungs would enhance suscep-
tibility to P. aeruginosa pneumonia, but these other host factors
would nonetheless provide a substantial measure of resistance
to lung infection. However, previously published studies have
not systemically tested this hypothesis with a range of P. aerugi-
nosa isolates in a setting of neutropenia induced by specific
PMN depletion or in animals unable to recruit PMN to the
lungs. We therefore utilized a model of acute P. aeruginosa
pneumonia in mice under these defined parameters to study
the relative contributions of host factors needed to resist de-
velopment of lung infection, systemic spread of bacteria, and
death. By either chemically administered or genetically in-
duced immunosuppression—via systemic chemotherapy that
resulted in neutropenia, lymphopenia, and epithelial cell mu-
cosal damage (cyclophosphamide), specific neutrophil deple-
tion (RB6-8C5 MAb), which also induced a modest lymphope-
nia, lack of mature lymphocytes (Rag1/ mice), alveolar
macrophage depletion (via liposomal clodronate), or an inabil-
ity to recruit PMNs to the lungs (MyD88/ mice)—followed
by i.n. P. aeruginosa infection with very low bacterial doses, we
found PMNs to be unassailably essential for host resistance to
lung infection and death from P. aeruginosa. Infectious doses
as low as 8 CFU/mouse for some P. aeruginosa strains resulted
in high levels of lung infection and death, with doses of 120
CFU/mouse of all P. aeruginosa strains evaluated being nearly
100% lethal in the absence of effective neutrophil numbers or
recruitment to the lungs. Importantly, we found this nearly
absolute requirement for PMNs was manifest in C3H mice,
which do not show the T helper cell biases of other strains,
such as C57BL/6 (43) and BALB/c (43), although we did use
the former strain to also show that Myd88 deficiency, which
FIG. 7. Murine BAL fluid analysis for the presence of neutrophils
in lung sections from MyD88/ mice administered various bacterial
preparations. BAL fluid from 6- to 8-week-old female MyD88/ mice
was obtained 24 h after i.n. administration of the following: 50 CFU of
P. aeruginosa strain PAO1 (A); 10 g of E. coli strain 0111:B4 LPS (B);
108 CFU of paraformaldehyde-killed E. coli strain HB101 (C); 10 g of
poly(I:C) (D); 108 CFU of live E. coli strain HB101 (E). Differential
cell counts were determined from Wright-Giemsa-stained cytospins
(100 cells per slide were counted). Objective lens, 10. Only panel E
shows the presence of polymorphonuclear lymphocytes in the BAL
fluid.
FIG. 8. Survival curves of MyD88 / mice after i.n. administration
of live or paraformaldehyde (PAF)-killed E. coli strain HB101 fol-
lowed by challenge with 38 CFU of P. aeruginosa strain PAO1 or 256
CFU of strain PA14 i.n. The RB6, live HB101 group was given MAb
RB6-8C5, 0.200 mg i.p., once on day zero, E. coli strain HB101 i.n. on
day 1 (24 h); or 38 CFU of PAO1 i.n. on day 2 (48 h). Median survival
of mice given live HB101 and subsequent i.n. P. aeruginosa was higher
than that of mice treated with PAF-HB101 (P  0.0012 for PAO1
group, log rank test). Each group contained eight mice. Values in
parentheses indicate the average P. aeruginosa inoculum CFU.
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abrogates PMN recruitment to an infected lung, was also a
major factor in resistance of this mouse strain to P. aeruginosa
lung infection. Although no single manipulation of the murine
immune system provided an absolute setting wherein only neu-
tropenia was present without other immune system factors
affected, the only common factor among the five experimental
settings we tested that resulted in profound susceptibility to
low doses of P. aeruginosa was neutropenia. These results im-
ply that among the host factors commonly invoked to explain
innate resistance to P. aeruginosa pneumonia, or the expecta-
tion that protective effects from factors such as mucociliary
clearance, antimicrobial peptides, surfactants, and the like
could augment resistance to P. aeruginosa lung infection in
mice, we found only lung-recruited neutrophils to have an
essential and critical role in clearing very low challenge doses
of P. aeruginosa from the mouse lung.
The lack of resistance of neutropenic mice to P. aeruginosa
is striking when compared to mice with intact neutrophil num-
bers and function. The 50% lethal dose (LD50) for P. aerugi-
nosa strain PAO1 in this murine model of acute P. aeruginosa
pneumonia in normal 6- to 8-week-old female C3H/HeN mice
is 3  107 CFU, for strain IT4 it is 6  108 CFU, and for strain
170003 it is 8 107 CFU (40). Remarkably, when giving either
Cy or MAb RB6-8C5 followed by a very-low-dose i.n. inoculum
of one of these P. aeruginosa strains, 62.5% to 100% mortality
was achieved. In many cases there was a 6- to nearly 8-log
decrease in inoculum needed to achieve lethality in 50% or
more of the animals. Perhaps the most notable example is
strain IT4, which is relatively avirulent in intact mice (LD50,
6 108 CFU/mouse), but 8 to 10 CFU applied to the nose was
lethal to 62.5% to 75% of neutropenic mice. Likewise, based
on work previously done in this laboratory utilizing the same
murine model of acute pneumonia, the LD50 for PA14 is 3 
106 CFU (1, 39, 40), and the LD100 for N13 is 5  10
7 CFU
(36). Thus, this acute susceptibility of neutropenic mice to
low-inoculum P. aeruginosa acute pneumonia does not appear
to be relegated to one or two strains but is generalizable to all
seven strains used in this study.
Recently, Jayaseelan and colleagues (21) demonstrated that
neutrophils are crucial in controlling P. aeruginosa lung infec-
tion by showing enhanced susceptibility to infection and death
of both MyD88-deficient mice and WT mice treated with MAb
RB6-8C5; the study, however, only utilized one strain of P.
aeruginosa (PAO1) and administered a much higher inoculum
(1  106 CFU) than what we used. Similarly, others have
previously established that neutropenia induced by either Cy
or MAb RB6-8C5 lowers the inoculum of P. aeruginosa needed
to produce pneumonia and sepsis (49, 55), but no systematic
study of the relative contributions of neutrophils versus other
mediators of innate immunity were analyzed. Again, only one
strain of P. aeruginosa for each treatment was used in these
other studies, whereas we used a range of strains, including
numerous clinical isolates, and the inoculum used in one of
these studies was also substantially higher (1  106 CFU) (55).
We initially evaluated susceptibility of mice to P. aeruginosa
lung infection following induction of neutropenia by Cy, as this
agent has been used to induce neutropenia in prior models of
P. aeruginosa infection (49). However, as Cy produces neutro-
penia (24), lymphopenia (24), and mucosal damage (6), its use
often makes it unclear what components of the innate immune
system are truly critical for preventing acute P. aeruginosa
pneumonia. As evidenced in Fig. 1B, Cy resulted in profound
neutropenia, lymphopenia, and monocytopenia in the mice
that we tested. We thus compared effects of Cy treatment to
the more specific PMN-depleting agent MAb RB6-8C5. Neu-
trophil depletion by MAb RB6-8C5 has been used in a number
of animal models of infection (4, 8, 14, 56) and reacts with a
common epitope on Ly-6G and Ly-6C. In the peripheral blood,
MAb RB6-8C5 recognizes granulocytes (neutrophils and eo-
sinophils) and monocytes (12, 26, 57). Although the absolute
lymphocyte count also decreased after administration of RB6-
8C5 MAb, counts were generally over 1,000 cells/mm3 (Fig. 4)
and the degree of lymphopenia was not as profound (100
cells/mm3) as that seen with Cy administration (Fig. 1B). RB6-
8C5 MAb has also been reported to almost completely elimi-
nate a subset of Ly-6C memory-type CD8 T cells (31).
Therefore, to determine if the decreased lymphocyte count
could contribute to the increased susceptibility to P. aeruginosa
pneumonia, we used Rag1/ mice and found that a lack of
mature lymphocytes made only a very modest contribution to
the increased susceptibility to acute P. aeruginosa pneumonia.
This was evidenced by the finding that an i.n. inoculum of 9.2
106 CFU of P. aeruginosa strain PAO1 resulted in 100% mor-
tality for Rag1/ mice and only 37.5% mortality in WT mice.
Interestingly, a 70% reduction in inoculum resulted in 100%
survival for both Rag1/ and WT mice, and yet a 0.5-log
increase in inoculum resulted in 0% survival for both groups.
This steep dose-response curve has been observed with other
strains of P. aeruginosa in this model (unpublished observa-
tion). Although lack of mature lymphocytes modestly in-
creased susceptibility to acute P. aeruginosa infection, this was
not nearly as dramatic as the 6- to 7-log-increased susceptibility
to P. aeruginosa infection found in the setting of neutropenia
or an inability to recruit PMNs to the lungs.
Alveolar macrophages have long been considered one of the
first lines of defense against microorganisms that reach the
lower respiratory tract. Several receptors (i.e., Fc receptors,
complement receptors 1 and 3, and mannose-binding lectin
receptor) have been identified and associated with phagocyto-
sis of P. aeruginosa (46, 54), and multiple mechanistic steps
involved with AM phagocytosis of P. aeruginosa have been
elucidated (27, 53). However, a direct role for AM in surviving
acute P. aeruginosa infection seems to be minor (9, 25). One
study (25) showed continued administration of liposomal clo-
dronate resulted in persistent neutrophilic alveolitis and de-
creased bacterial clearance, leading those authors to conclude
that macrophages were critical for coordinating the innate
immune response (in particular, recruitment of neutrophils) in
acute P. aeruginosa infection, but there was no overall differ-
ence in mortality between mice with sufficient or depleted AM.
Consistent with these findings, we saw no effect on mortality
following liposomal clodronate depletion of AM in mice
given 6  106 CFU of P. aeruginosa i.n.
To implicate PMNs further as the essential mediators of
resistance to P. aeruginosa pneumonia, we administered
r-mGCSF to neutropenic mice to see if we could augment
resistance to an otherwise-fatal dose of P. aeruginosa by stim-
ulating the proliferation, differentiation, and release of granu-
locytes from the bone marrow. We were able to markedly
increase circulating neutrophils in mice treated with r-mGCSF
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after depletion of PMNs with RB6-8C5 MAb and reduce the
mortality from i.n. P. aeruginosa administration. These results
are similar to those reported by others who have used G-CSF
in neutropenic mice infected with P. aeruginosa (2), but higher
bacterial challenge doses or coadministration of antibiotics or
defensins were also studied in these other experimental pro-
tocols. Human G-CSF has been used to treat neutropenic
patients with a wide range of clinical conditions (35) and has
shown benefit in resisting P. aeruginosa infection, and G-CSF is
often induced during infections in both mice (41) and humans
(22). It should be noted, however, that G-CSF not only stim-
ulates the bone marrow to produce neutrophils but also stem
cells. This may explain why both murine lymphocyte and
monocyte counts also increased after administration of
r-mGCSF (Fig. 4).
Given that the absolute number of circulating neutrophils
appears to be critical in the defense against acute P. aeruginosa
lung infection, the next logical step was to investigate the
importance of neutrophil recruitment. We previously showed
that Myd88 is needed for the rapid nuclear translocation of
NF-
 following P. aeruginosa lung infection (45), which leads
to production of interleukin-6 and interleukin-8 and increases
in intercellular adhesion molecule 1, all factors needed for
PMN recruitment (44). Here we found that MyD88-deficient
mice exhibited a nearly complete deficit in neutrophil recruit-
ment to the lung following P. aeruginosa infection and were
nearly as susceptible to lethal pneumonia and sepsis as were
neutropenic mice. We confirmed that the MyD88/ mice had
normal numbers of PMNs in the systemic circulation compared
to wild-type C57BL/6 mice (A. Y. Koh and G. B. Pier, unpub-
lished observation). However, when PMNs were recruited to
the lungs via a MyD88-independent pathway by prior admin-
istration of live E. coli HB101, we could augment resistance of
MyD88/ mice to low-dose P. aeruginosa infection. This did
not occur in either mice pretreated with paraformaldehyde-
killed E. coli HB101, which failed to induce PMN recruitment
in MyD88/ mice or in MyD88-deficient mice given live, i.n.
E. coli HB101 to augment PMN entry into the lungs but also
given MAb RB6-8C5 to deplete PMNs. This finding indicates
that PMN recruitment into the lungs following infection with
P. aeruginosa is nearly completely dependent on MyD88-me-
diated signaling.
Prior studies of P. aeruginosa infection in MyD88/ mice
(38, 52) showed blunted early cytokine production and inflam-
matory responses and development of fatal pneumonia with P.
aeruginosa (52), but these studies did not look at low infectious
inocula and their ability to cause infection and dissemination.
The study of Skerrett et al. (52) utilized only a single bacterial
strain and a high aerosol inoculum to indicate an important
role for MyD88 in resistance to P. aeruginosa lung infection but
did not analyze the degree to which the MyD88/ mice were
more susceptible to P. aeruginosa in terms of the effect of
infectious inocula. Another study showed reduced early clear-
ance of a single P. aeruginosa strain in MyD88/ mice (38),
but this factor was dispensable for delayed clearance (37),
wherein recruitment of neutrophils into the lung operated via
an MyD88-independent mechanism (e.g., TLR-TRAM/TRIF
pathway). However, this latter study used a mucoid, LPS rough
clinical isolate of P. aeruginosa that does not readily cause, and
is not representative of the strains that are isolated from cases
of, ventilator-associated acute pneumonia and sepsis, and it is
also a strain that can be cleared from the lungs and blood due
to its sensitivity to the bactericidal effects of complement.
Thus, this finding in MyD88/ mice is not completely appli-
cable to the setting of acute P. aeruginosa pneumonia with LPS
smooth, nonmucoid, serum-resistant strains. Notably, a recent
report documented nine children with autosomal recessive
MyD88 deficiency that experienced severe, often life-threaten-
ing pyogenic bacterial infections with pathogens, including P.
aeruginosa, Streptococcus pneumoniae, and Staphylococcus au-
reus (60), indicating that MyD88 is also important in human
resistance to P. aeruginosa infection. Finally, there are several
studies that support the notion that most of the initial coloniz-
ing strains in patients with cystic fibrosis tend to be nonmucoid
and LPS smooth (5, 16, 29).
Our findings and conclusions clearly challenge some well-
established dogmas in regard to host resistance to P. aeruginosa
lung infection, wherein factors other than PMNs have been
implicated as making a significant contribution to clearing this
pathogen from the lung. These include structural (integumen-
tary) barriers provided by respiratory tract epithelial cells, mu-
cociliary clearance (61), and antimicrobial molecules (i.e., de-
fensins [50], lysozyme [10], lactoferrin [47], and collectins [19]).
It is possible that extending our findings and conclusions to
humans requires appropriate caution, particularly with regard
to mucociliary clearance. For example, the absolute size of a P.
aeruginosa cell is the same whether infecting a mouse or hu-
man, but the smaller amount of tissue providing mucociliary
clearance in a mouse versus the much larger tissue area in a
human may mean that 10 CFU of P. aeruginosa given i.n. to a
neutropenic mouse is able to overcome the mucociliary de-
fense system of this species, whereas mucociliary clearance in
a neutropenic human may be more effective in resisting low-
dose infections. Similarly, antimicrobial molecules may have a
more prominent role in human defense against acute P. aerugi-
nosa pulmonary infection that we could not demonstrate in our
mouse model. However, as almost all experimental studies of
mammalian resistance to P. aeruginosa infection use mice, and
essentially all studies to date in transgenic animals use mice,
the utility of this species for such studies is considered to
provide a strong basis for insights into human resistance and
susceptibility to this pathogen.
In conclusion, by utilizing a murine model of acute P. aerugi-
nosa pulmonary infection and manipulating distinct arms of
the cellular innate immune system (i.e., neutrophils, AM, and
mature lymphocytes) under five different experimental condi-
tions, we found that the lack of effective PMN activity in the
lungs was the one factor common to these conditions that
allowed for the extreme susceptibility to a lethal P. aeruginosa
lung infection. Thus, despite the fact that the pulmonary innate
defense system is a complicated amalgam of structural barriers,
mucociliary clearance, antimicrobial molecules produced in
the airways, and cellular defenses, ultimately PMNs, and in
particular recruitment of PMNs to the lung, are the component
of the innate host defense needed for resisting very low doses
of P. aeruginosa in an acute model of pulmonary infection. In
the absence of circulating PMNs, or PMN recruitment into the
lung, fatal infections can be induced by aspiration of very small
inocula of P. aeruginosa.
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